De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
SciVision Biotech Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
SciVision Biotech heeft een totaal eigen vermogen van NT$1.7B en een totale schuld van NT$206.1M, wat de schuld-eigenvermogensverhouding op 12.1% brengt. De totale activa en totale passiva bedragen respectievelijk NT$2.3B en NT$632.9M. De EBIT SciVision Biotech is NT$232.4M waardoor de rentedekking -19.8 is. Het heeft contanten en kortetermijnbeleggingen van NT$861.3M.
Belangrijke informatie
12.1%
Verhouding schuld/eigen vermogen
NT$206.13m
Schuld
| Rente dekkingsratio | -19.8x |
| Contant | NT$861.28m |
| Aandelen | NT$1.70b |
| Totaal verplichtingen | NT$632.94m |
| Totaal activa | NT$2.33b |
Recente financiële gezondheidsupdates
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Recent updates
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( NT$1.2B ) 1786 } overtreffen de korte termijn passiva ( NT$362.3M ).
Langlopende schulden: De kortetermijnactiva 1786 ( NT$1.2B ) overtreffen de langetermijnschulden ( NT$270.6M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 1786 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 1786 is de afgelopen 5 jaar gedaald van 22.1% naar 12.1%.
Schuldendekking: De schuld van 1786 wordt goed gedekt door de operationele kasstroom ( 145.3% ).
Rentedekking: 1786 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.